Oticlor 500 Capsule : Each capsule contains Cefaclor Monohydrate USP 524.46 mg equivalent to Cefaclor 500 mg.
Oticlor Dry suspension: After reconstitution, each 5 ml suspension contains Cefaclor Monohydrate USP 131.11 mg equivalent to Cefaclor 125 mg.
Oticlor Paediatric drops: After reconstitution, each ml drop contains Cefaclor Monohydrate USP 104.9 mg equivalent to Cefaclor 100 mg.
Cefaclor, a second generation cephalosporin, demonstrates the bactericidal action by inhibiting cell wall synthesis. It is active against the following organisms In Vitro:
Aerobes, Gram-positive: Streptococcus pneumoniae, Streptococcus pyogenes (Group A beta-haemolytic streptococci) and Staphylococci.
Aerobes, Gram-negative: Moraxella catarrhalis, Haemophilus influenzae, Escherichia coli, Proteus mirabilis, Klebsiella sp.,Citobacter diversus and Neisseria gonorrhoeae.
Anaerobes: Propionibacteria acnes, Bacteroides sp. (excluding Bacteroides fragilis), Peptococci and Peptostreptococcus sp.
Oticlor is indicated in the treatment of the following infections:
Lower respiratory tract infections, including pneumonia, bronchitis and acute exacerbation of chronic bronchitis
Upper respiratory tract infections, including pharyngitis and tonsillitis
Urinary tract infections, including pyelonephritis and cystitis
Skin and soft tissue infections
Oticlor is administered orally.
Children: The usual recommended dosage for children is 20 mg/kg/day in divided doses every 8 hours. The dose of Oticlor suspension and paediatric drops for children is given in the following:
Age Oticlor suspension Oticlor Paediatric Drops
1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d
1 year - 5 year 5 ml t.i.d. 1.25 ml t.i.d
over 5 years 10 ml t.i.d 2.5 ml t.i.d
In more serious infections, such as otitis media, or those caused by less susceptible organisms, 40 mg/kg/day is recommended, with a maximum dosage of 1 gm/day. Safety and efficacy have not been established for use in infants aged less than 1 month.
Adults: The usual adult dose is 250 mg every 8 hours. For bronchitis, the dosage is 250 mg administered 3 times daily. A dosage of 250 mg administered 3 times daily for 10 days is recommended for sinusitis. For more severe infections, such as pneumonia, or those caused by less susceptible organisms, dose may be doubled.
Cefaclor may be administered safely in the presence of impaired renal function. Under such conditions, dosage is usually unchanged.
Most adverse effects reported with Cefaclor are similar to those reported with other oral cephalosporins. The most frequent adverse effects reported include gastrointestinal effects (nausea, vomiting, diarrhea) headache and rash. Rarely, Serum sickness-like reactions consisting of erythema multiforme, urticaria accompanied by arthritis, arthralgia, irritability and fever have been reported.
Cefaclor should be administered with caution in the presence of markedly impaired renal function. Dosage adjustments for patients with moderate or severe renal impairment are not usually required.
Pregnancy: Animal studies have shown no evidence of impaired fertility or teratogenicity. However, since there are no adequate or well-controlled studies in pregnant women, caution should be exercised when prescribing for the pregnant women.
Lactation: Small amount of Cefaclor have been detected in breast milk following administration of single 500 mg dose. As the effect on nursing infants is not known, caution should be exercised when Cefaclor is administered to a nursing woman.